Cite
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
MLA
Oka, Yoshihiro, et al. “Wilms Tumor Gene Peptide-Based Immunotherapy for Patients with Overt Leukemia from Myelodysplastic Syndrome (MDS) or MDS with Myelofibrosis.” International Journal of Hematology, vol. 78, no. 1, July 2003, pp. 56–61. EBSCOhost, https://doi.org/10.1007/BF02983241.
APA
Oka, Y., Tsuboi, A., Murakami, M., Hirai, M., Tominaga, N., Nakajima, H., Elisseeva, O. A., Masuda, T., Nakano, A., Kawakami, M., Oji, Y., Ikegame, K., Hosen, N., Udaka, K., Yasukawa, M., Ogawa, H., Kawase, I., & Sugiyama, H. (2003). Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. International Journal of Hematology, 78(1), 56–61. https://doi.org/10.1007/BF02983241
Chicago
Oka, Yoshihiro, Akihiro Tsuboi, Masaki Murakami, Manabu Hirai, Nobuhiko Tominaga, Hiroko Nakajima, Olga A Elisseeva, et al. 2003. “Wilms Tumor Gene Peptide-Based Immunotherapy for Patients with Overt Leukemia from Myelodysplastic Syndrome (MDS) or MDS with Myelofibrosis.” International Journal of Hematology 78 (1): 56–61. doi:10.1007/BF02983241.